Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase III, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

被引：0
|
作者：
Blauvelt, A. [1 ]
Wollenberg, A. [2 ]
Pink, A. [3 ]
Peris, K. [4 ,5 ]
Armstrong, A. [6 ]
Spelman, L. [7 ,8 ]
Saeki, H. [9 ]
Lynde, C. [10 ,11 ]
Herranz, P. [12 ]
Barbarot, S. [13 ]
Simpson, E. [14 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Ludwig Maximilian Univ Munich, Dept Dermatol & Allergol, Munich, Germany
[3] Guys & St Thomas Hosp, St Johns Inst Dermatol, London, England
[4] Catholic Univ, Dermatol, Rome, Italy
[5] IRCCS, Fdn Policlin Univ A Gemelli, Rome, Italy
[6] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA
[7] Verac Clin Res, Brisbane, Qld, Australia
[8] Prob Med Res, Woolloongabba, Qld, Australia
[9] Nippon Med Sch, Dept Dermatol, Tokyo, Japan
[10] Prob Med Res, Lynde Dermatol, Markham, ON, Canada
[11] Univ Toronto, Dept Med, Toronto, ON, Canada
[12] Hosp Univ La Paz, Dept Dermatol, Madrid, Spain
[13] Ctr Hosp Univ Nantes, Nantes, France
[14] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2021年 / 185卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
447
引用
收藏
页码：E110 / E111
页数：2
相关论文
共 50 条
  • [1] Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)
    Blauvelt, Andrew
    Wollenberg, Andreas
    Pink, Andrew
    Peris, Ketty
    Gemelli, A.
    Armstrong, April
    Spelman, Lynda
    Saeki, Hidehisa
    Lynde, Charles
    Herranz, Pedro
    Barbarot, Sebastien
    Simpson, Eric
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB177 - AB177
  • [2] Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
    Wollenberg, A.
    Blauvelt, A.
    Guttman-Yassky, E.
    Worm, M.
    Lynde, C.
    Lacour, J. -P.
    Spelman, L.
    Katoh, N.
    Saeki, H.
    Poulin, Y.
    Lesiak, A.
    Kircik, L.
    Cho, S. H.
    Herranz, P.
    Cork, M. J.
    Peris, K.
    Steffensen, L. A.
    Bang, B.
    Kuznetsova, A.
    Jensen, T. N.
    osterdal, M. L.
    Simpson, E. L.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 437 - 449
  • [3] Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial
    Silverberg, J. I.
    Toth, D.
    Bieber, T.
    Alexis, A. F.
    Elewski, B. E.
    Pink, A. E.
    Hijnen, D.
    Jensen, T. N.
    Bang, B.
    Olsen, C. K.
    Kurbasic, A.
    Weidinger, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 450 - 463
  • [4] Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
    Simpson, Eric L.
    Merola, Joseph F.
    Silverberg, Jonathan, I
    Reich, Kristian
    Warren, Richard B.
    Staumont-Salle, Delphine
    Girolomoni, Giampiero
    Papp, Kim
    de Bruin-Weller, Marjolein
    Thyssen, Jacob P.
    Zachariae, Rebecca
    Olsen, Christiana K.
    Wollenberg, Andreas
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (06) : 888 - 899
  • [5] EFFICACY AND SAFETY OF TRALOKINUMAB IN A KOREAN SUBPOPULATION OF PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: A SUBANALYSIS OF ECZTRA 2, A PHASE 3, MONOTHERAPY, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED TRIAL
    Kim, Kyu Han
    Son, Sang Wook
    Lee, Yang Won
    Simpson, Eric L.
    Kuznetsova, Alexandra
    Cho, Sang Hyun
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 63 - 63
  • [6] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Tyring, Stephen K. K.
    Rich, Phoebe
    Tada, Yayoi
    Beeck, Stefan
    Messina, Izabella
    Liu, Jie
    Huang, Xiaohong
    Shumack, Stephen
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
  • [7] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Stephen K. Tyring
    Phoebe Rich
    Yayoi Tada
    Stefan Beeck
    Izabella Messina
    Jie Liu
    Xiaohong Huang
    Stephen Shumack
    Dermatology and Therapy, 2023, 13 : 595 - 608
  • [8] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: results from two phase III, randomized, double-blinded, placebo-controlled trials
    Silverberg, Jonathan I.
    Thaci, Diamant
    Seneschal, Julien
    Gold, Linda Stein
    Blauvelt, Andrew
    Simpson, Eric
    Chu, Chia-Yu
    Liu, Zhuqing T.
    Lima, Renata Gontijo
    Pillai, Sreekumar
    Guttman-Yassky, Emma
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E97 - E98
  • [9] The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
    Zhao, Y.
    Wu, L.
    Lu, Q.
    Gao, X.
    Zhu, X.
    Yao, X.
    Li, L.
    Li, W.
    Ding, Y.
    Song, Z.
    Liu, L.
    Dang, N.
    Zhang, C.
    Liu, X.
    Gu, J.
    Wang, J.
    Geng, S.
    Liu, Q.
    Guo, Y.
    Dong, L.
    Su, H.
    Bai, L.
    O'Malley, J. T.
    Luo, J.
    Laws, E.
    Mannent, L.
    Ruddy, M.
    Amin, N.
    Bansal, A.
    Ota, T.
    Wang, M.
    Zhang, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 633 - 641
  • [10] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
    Torrelo, A.
    Rewerska, B.
    Paller, Amy
    Prakash, A.
    Zhu, D.
    Pontes, M.
    Wu, Wen-Shuo
    Eichenfield, Lawrence F.
    Boecker, Ulrike
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
12345